| | ACS | | | Prevent The Event: Role of Oral Antiplatelet Therapy in the Management of the ACS Patient
Overview
The term acute coronary syndrome (ACS) is used to describe patients who present with either acute MI or unstable angina (UA). This program will provide an overview of ACS by discussing epidemiology, prevalance, acute and long term care treatment options as well as review current guidelines. Implementation of current treatment guidelines and patient adherence strategies in the primary care setting will also be discussed.
Objectives
Name 5 treatment recommendations for reduction of global CV risk in patients being medically managed for UA/NSTEMI
Describe 2 situations where dual antiplatelet therapy is recommended in patients with acute coronary syndrome
Faculty
F. Wilford Germino, MD, FACP
Department of Internal Medicine
Orland Primary Care Specialists
Orland Park, IL
Lawrence E. Mieczkowski, MD
Clinical Associate Professor of Medicine
Wright State University School of Medicine
Medical Director, Center for Cardiometabolic Treatment
Dayton, OH
| | | Dyslipidemia | | | The Moving LDL Target: Getting Your Patients to Goal
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
Benjamin J. Ansell, MD
Director, UCLA Center for Primary Care-Based Cardiovascular Disease Prevention
Associate Professor of Internal Medicine
University of California, Los Angeles (UCLA) School of Medicine
Los Angeles, CA
Ronald A. Codario, MD, FACP
Clinical Instructor in Medicine
Thomas Jefferson University Hospital
Philadelphia, PA
| | | Insomnia | | | Insomnia: New Directions in Evaluation and Treatment
Overview
Despite a high prevalence in the United States, insomnia remains underdiagnosed and undertreated. Extensive research has identified several factors that contribute to the inadequate treatment of insomnia, including the failure of patients to report insomnia to clinicians and clinician misperceptions about the risks associated with hypnotic medications. This program will address effective strategies for diagnosing and treating patients with insomnia.
Objectives
Identify risk factors, determine appropriate screening tools, and accurately diagnose insomnia
Evaluate current and emerging nonpharmacologic and pharmacologic therapies for acute and chronic insomnia on the basis of efficacy and safety and apply this knowledge/skill with patients
Faculty
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine, Jefferson Medical College
Philadelphia, PA
Thomas Neylan, MD
| | | Zoster Virus | | | Preventing Herpes Zoster and Postherpetic Neuralgia: Are Your Patients Adequately Protected?
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the epidemiology and public health burden of herpes zoster and its most common complication, postherpetic neuralgia (PHN)
Discuss the benefits and limitations of current pharmacotherapies for herpes zoster and Postherpetic neuralgia (PHN), and evaluate clinical trial data on the efficacy and safety of herpes zoster vaccination
Faculty
John F. Trowbridge, MD, CPE
Director, Chronic Conditions Management
Kaiser Permanente Santa Rosa
Clinical Professor of Medicine
University of California at San Francisco
San Francisco, CA
Stephen Allred, ANP
| | | HPV | | | Reducing the Burden of HPV-Related Diseases: Cervical Cancer and Beyond
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
Daron G. Ferris, MD
Professor
Department of Family Medicine
Department of Obstetrics and Gynecology
Director, Gynecologic Cancer Prevention Center
Medical College of Georgia
Augusta, GA
J. Thomas Cox, MD
Director, The Women's Health Clinic
Student Health Services
University of California, Santa Barbara
Santa Barbara, CA
| | | Menstrual Migraine | | | A Practical Approach to Managing Menstrual Migraine: Tailoring Treatment and Individualizing Care
Overview
Migraine is a chronic, debilitating disorder that affects approximately 28 million Americans of whom ~18% are women and ~6% are men. When compared to migraines that occur during other times of the month, menstrual migraine (MM) may last longer and be more severe, disabling, frequent, and more difficult to treat. This program will address the new advances in the understanding of MM, the role of hormones, and how to select an appropriate treatment based on individual patient characteristics.
Objectives
Recognize migraine in the differential diagnosis of headaches that impact patients ability to fully function in their daily activities and identify menstrual migraine in female patients
Identify management strategies for women with menstrual migraine including use of headache calendars, behavioral modifications and approaches to acute and preventive treatment
Faculty
Brian Koffman, MDCM
Clinical Professor, Department of Family Medicine
Keck School of Medicine, USC Family Practice
St. Jude Heritage Medical Group
Diamond Bar, CA
Vincent Martin, MD
Professor of Clinical Medicine, University of Cincinnati
Cincinnati, OH
| | | Chronic Constipation | | | Up-to-the-Second Advances in the Primary Care Management of Chronic Constipation and Other Functional Bowel Disorders
Overview
Chronic Constipation is a multi-symptom gastrointestinal motility disorder that negatively impacts the lives of approximately 33 million Americans. Due to the overlap in symptoms reported by patients with irritable bowel syndrome-constipation and chronic constipation, clinicians often find it challenging to differentiate between the two. With a changing landscape of therapeutic options available, it is imperative that clinicians be able to establish and accurate diagnosis so the proper foundation is provided for determining initial therapy and developing a treatment plan.
Objectives
Differentiate chronic constipation from other functional bowel disorders
Identify the therapies that can be used to treat chronic constipation and other functional bowel disorders
Faculty
Roy K.H. Wong, MD
Chief of Gastroenterology
Walter Reed Army Medical Center
Professor of Medicine,
Director, Division of Digestive Diseases
Uniformed Services University of the Health Sciences
Washington, DC
David A. Peura, MD
Professor of Medicine
University of Virginia Health Sciences Center
Charlottesville, VA
| | | Pain Management | | | A Clinical Conversation: Diagnosis & Treatment of Neuropathic Pain
Overview
Four million people in the United States suffer from neuropathic pain, a condition that is often difficult to diagnose. This session, Clinical Conversation: Diagnosis & Treatment of Neuropathic Pain will address practical ways primary care physicians can improve recognition and treatment of neuropathic pain.
Objectives
Recognize signs and symptoms of neuropathic pain to increase identification of patients with neuropathic pain
Evaluate available treatment options for neuropathic pain and their appropriateness for your patient population to improve outcomes in these patients
Faculty
David Bazzo, MD
Assistant Clinical Professor of Family Medicine, University of California San Diego School Medicine
San Diego, CA
Bill McCarberg, MD
Clinical Assistant Professor of Medicine, Thomas Jefferson University in Philadelphia, PA, and Director, Lankenau Internal Medicine Clinical Care Center, Lankenau Hospital
Wynnewood, PA
| | | Hypogonadism | | | Hypogonadism: Under Reported and Under Diagnosed
Overview
Hypogonadism affects at least 20% of US men aged 50 years and older but is both under reported and under diagnosed. This program will explore the importance of hypogonadism and its comorbidities as a major health issue, review accurate diagnosis, discuss goals of treatment, and review available treatment options.
Objectives
Recognize that low serum testosterone is far more than a sexual dysfunction issue, acknowledge its association with other serious health conditions, such as metabolic syndrome, hypertension, renal failure, diabetes, and dyslipidemia, and have the improved ability to make an accurate diagnosis, as well as, describe the goals and benefits of TRT therapy and identify common misconceptions regarding the risks
Describe the benefits and limitations of different available delivery systems for TRT and emphasize the importance of regular patient monitoring
Faculty
Chad Ritenour, MD
Assistant Professor of Urology
Director, Outpatient Services
Director, Men's Health Center
The Emory Clinic
Atlanta, GA
| | | Hypertension | | | Management of the Moderate to Severe Hypertensive: Individualizing Treatment to Maximize Outcomes
Overview
This program will underscore the need for early, aggressive, combination BP treatment in order to reach JNC 7 goals, in light of the effect hypertension and diabetes has on the pathogenesis of hypertensive renal damage. It will explain the mechanisms of action of the various antihypertensive drug classes and how clinicians can use this understanding when selecting a drug regimen. Based on recent and ongoing trials, the safest and most efficacious drug combinations will be discussed.
Objectives
Develop appropriate combination therapy regimens individualized to each diabetic hypertensive patientŐs established risk and comorbid conditions
Demonstrate an understanding of the role of Renin-Aniotensin-Aldosterone System blockers in the treatment of hypertension, the prabsoevention of new onset diabetes, and prevention of progression in diabetic nephropathy by selecting the most appropriate treatment regimen for diabetic hypertensive patients
Faculty
Philip Altus, MD, MACP
Professor of Medicine Emeritus
University of South Florida
Tampa, FL
Domenic A. Sica, MD
Professor of Medicine
Medical College of Virginia
Virginia Commonwealth University
Richmond, VA
| | | Rhinitis | | | Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Healthcare Professional
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Alexander N. Greiner, MD
University of CA, San Diego, School of Medicine
San Diego, CA
Michael J. Welch, MD
University of California San Diego
San Diego, CA
| | | Diabetes | | | Running a Winning Campaign Against Type 2 Diabetes: Evidence Based Therapeutic Decisions on Glycemic Control and Cardiovascular Risk
Overview
More than 20 million people are affected by diabetes and of this population nearly 65% will suffer early cardiovascular death. To effectively treat diabetes and reduce the risk of a cardiovascular event, glucose levels must be monitored and quickly controlled through changes in intervention, as outlined by the ADA/EASD treatment algorithm. Recent data provided by the National Health and Nutrition Examination Surveys (NHANES) revealed that there is some overall improvement in reaching the appropriate treatment standards, however, with the number of diabetes cases increasing by 1.5 million each year and the recent labeling changes affecting therapeutic options, it is more important than ever to be familiar with the pharmacologic treatment options for type 2 diabetes and the associated cardiovascular risk.
Objectives
Identify the current goals for A1C, blood pressure, and lipid levels set forth by the American Diabetes Association and apply them to the treatment strategies listed on the ADA/EASD algorithm in an effort to choose the best therapeutic option for each individual patient
Assess when patients with type 2 diabetes require cardiovascular risk reduction in addition to glycemic control and develop evidence-based approaches to treatment based on the ADA/EASD algorithm by reviewing adverse events
Faculty
Richard Pratley, MD
Professor of Medicine
Director, Diabetes and Metabolism
Translational Medicine Unit
University of Vermont College of Medicine
Burlington, VT
Mark Stolar, MD
Associate Professor of Clinical Medicine
Northwestern University
The Feinberg School of Medicine
Chicago, IL
| | | Osteoarthritis | | | Optimal Use of Analgesics in the Management of Osteoarthritis Pain
Overview
Optimal Use of Analgesics in the Management of Osteoarthritis Pain will provide an evidence-based, guideline-based review of treatment options for managing osteoarthritis pain. Video-vignette, case-based learning will be used to illustrate education from expert presentations and guidelines. Special emphasis will be placed on physician-patient communication regarding pain management.
Objectives
Implement strategies for patient communication and education for management of OA pain and utilize pharmacologic and nonpharmacologic therapies for pain management according to guideline recommendations
Describe patient risk factors which could interact with various pain relief medications
Faculty
Javier C. Waksman, MD, DABT, FACMT
Associate Professor
Department of Medicine
University of Colorado Denver
Aurora, Colorado
Frank LoVecchio, DO, MPH
Professor
Arizona College of Osteopathic Medicine
Midwestern University
Glendale, Arizona
| | | | | |
Overview
Objectives
Faculty
|
|
